Mitazalimab plus mFOLFIRINOX in Metastatic Pancreatic Cancer: Insights from the OPTIMIZE-1 Study - OncoDaily Mitazalimab is CD40 monoclonal antibody, which showed effectiveness for advanced pancreatic cancer in combination with chemotherapy.

Mitazalimab plus mFOLFIRINOX in Metastatic Pancreatic Cancer: Insights from the OPTIMIZE-1 Study

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Mitazalimab #mFOLFIRINOX #PancreaticCancer

Summary of biomarker findings

a more comprehensive understanding of which patients are most likely to benefit from the combination of #mitazalimab & #mFOLFIRINOX

for untreated metastatic pancreatic cancer patients receiving #mitazalimab plus #mFOLFIRINOX: a tumor-intrinsic fibrosis gene signature, #mitazalimab-induced immune activation, and circulating tumor DNA (ctDNA) clearance.

Mitazalimab shows promising survival rates in cancer study - PharmaTimes Updated data from phase 2 study reveals survival benefit

#oncology #Mitazalimab #survivalrates #phase2study #survivalbenefit #AlligatorBioscience #phase2clincialtrial #OPTIMIZE1study #combinationtherapy #mFOLFIRINOX #metastaticpancreaticcancer #pancreaticcancer #pancreaticcancerpatients #clinicaltrials #drugdevelopment
pharmatimes.com/news/mitazal...

Alligator Bioscience reports survival benefit of mitazalimab with mFOLFIRINOX - PharmaTimes Comparison shows improved survival rates for pancreatic cancer treatment

#immunotherapy #AlligatorBioscience #mitazalimab #mFOLFIRINOX #pancreaticcancer #metastaticpancreaticadenocarcinomacancer #mPDAC #mPDACpatients #OPTIMIZE1trial #metastaticpancreaticcancertreatment #healthoutcomesresearch #ASCOGastrointestinalCancersSymposium
pharmatimes.com/news/alligat...